Previous close | 0.0100 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.2700 |
Strike | 260.00 |
Expiry date | 2024-11-15 |
Day's range | 0.0100 - 0.0100 |
Contract range | N/A |
Volume | |
Open interest | 1 |
We recently compiled the list of 25 Best Dividend Aristocrats Stocks According to Analysts. Since AbbVie Inc. (NYSE:ABBV) is part of our list, we have analyzed the stock in detail. The age-old debate of investing in dividend growth or high-yield stocks continues to reappear within the dividend investing realm. Between these two, dividend growth is currently […]
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE®) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9% (95%CI 40.4 – 63.3%).